10x Genomics, Inc. Form 8-K Summary
Business context and reporting period
10x Genomics filed this Current Report on Form 8-K on February 15, 2023, under Item 2.02 to announce financial results for the fourth quarter and full year ended December 31, 2022. The filing covers the company’s Class A common stock, traded on Nasdaq under the symbol TXG.
Financial results and key metrics
The filing states that the company issued a press release announcing fourth-quarter and full-year 2022 financial results. The provided filing text does not include the press release’s financial tables or clear values for revenue, profit or loss, cash flow, margins, debt, liquidity, or other operating metrics.
Material changes versus the prior comparable period
The filing text does not provide a clear comparison with the fourth quarter or full year of 2021.
Guidance, outlook, risks, contingencies, and unusual items
The provided text does not include management’s guidance, outlook, risk discussion, contingencies, or unusual items. These details may be contained in Exhibit 99.1, the February 15, 2023 press release, which is referenced but not included in the supplied content.
Important facts for investors to verify
- Review Exhibit 99.1 for the reported fourth-quarter and full-year 2022 financial results.
- Verify revenue, gross margin, operating expenses, net loss, adjusted results, and cash-flow figures.
- Check year-over-year changes and management’s guidance or outlook for 2023.
- Review cash, investments, debt, liquidity, stock-based compensation, and other non-GAAP adjustments.
- Note that the Item 2.02 information and attached press release were furnished, not filed, for purposes of Section 18 of the Exchange Act, except as expressly incorporated by reference.